Top 5 Heal Care Stocks To Watch Right Now

For small businesses all across the U.S., business conditions will get better this year, most noticeably in the second half, when the overall economy shifts into higher gear. The rate of improvement will vary, of course, depending on the type of small business, where it��s located and the customers that it serves.

See Also: Kiplinger's Economic Outlooks

Among the fastest gainers: App developers, software firms, a variety of professional service firms in accounting, insurance, architecture, etc., and restaurants, including a growing number of franchises that serve fast food, from hamburgers to salads.

Two sectors to note, in particular, are housing and tourism. As housing sales continue to rev up, smalls serving construction will see increased orders for building materials, equipment rentals and more. One Maryland-based developer of specialized software for construction firms tells us he��s seeing sales pick up as builders ramp up for higher levels of activity.

Top 5 Heal Care Stocks To Watch Right Now: TD Ameritrade Holding Corporation(AMTD)

Advisors' Opinion:

• [By Spencer Israel]

  5. TD Ameritrade Holding Corp. (NASDAQ: AMTD) - Analysts are neutral on the brokerage firm, which has been in a trading range from $24-$32 for most of the year. The stock has also had low volatility, and the Street's confidence is at 69%. 

• [By Matthew Smith]

  Although we were not surprised by the move yesterday we did not take an overly aggressive stance in positioning the portfolio to benefit from the Fed not tapering. We were long, but we did not initiate any trades solely for the purpose to benefit from the announcement. We are more interested in the long-term wealth building of portfolios right now and as such believe that readers should look to our recent winners that had pullbacks yesterday as buying opportunities. Specifically, we like Ameritrade (AMTD), Charles Schwab (SCHW) and MetLife (MET) which all saw pullbacks ranging from 2.5% to a bit over 5.5% in yesterday's session. We highlighted the discount brokers as a sector to watch right before the latest takeoff and our belief is that although rates remain unchanged the brokerage business will continue to perform strongly. The next big move up will be as rates rise, but even if one has to wait for this move it will be well worth it for one's portfolio.

Top 5 Heal Care Stocks To Watch Right Now: TESARO, Inc.(TSRO)

Advisors' Opinion:

• [By Ben Levisohn]

  Who has PARP? A poly ADP-ribose polymerase inhibitor (PARPi) kills cancer cells by interfering tumor DNA repair pathway with the potential to treat ovarian, breast and prostate cancer. Studies have shown that patients with BRCA mutations (BRCAmut) respond to PARPi. AstraZeneca��s (AZN) PARPi was approved in 2014 while�Clovis Oncology (CLVS) and Tesaro (TSRO) both have positive Phase III data. Clovis licensed its PARPi from Pfizer (PFE) in 2011 and Tesaro licensed its PARPi from Merck (MRK) in 2012, after Sanofi��s (SNY) PARPi (later demonstrated that it cannot block PARP) failed in Phase III in early 2011.

• [By Ben Levisohn]

  Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

  Getty Images

  We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

  We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

  Ex M&A,

• [By Ben Levisohn]

  Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

Top 5 Heal Care Stocks To Watch Right Now: Insperity, Inc.(NSP)

Advisors' Opinion:

• [By Lee Jackson]

  Insperity Inc. (NYSE: NSP) also had a large-scale seller on the desk, and it was another well-known hedge fund. Value Act, which also serves as a director at the company, sold a total of 226,000 shares of the stock at prices that ranged from $71.22 to $72.41. The total for the sale was set at $16 million.�Insperity provides an array of human resources and business solutions to enhance business performance for small and medium-sized businesses in the United States. The shares closed the day on Friday at $71.85.

Top 5 Heal Care Stocks To Watch Right Now: Gibraltar Industries, Inc.(ROCK)

Advisors' Opinion:

• [By Lisa Levin]

  On Friday, the basic materials sector proved to be a source of strength for the market. Top gainers in the sector included LSB Industries, Inc. (NYSE: LXU), Ferro Corporation (NYSE: FOE), and Gibraltar Industries Inc (NASDAQ: ROCK).

Top 5 Heal Care Stocks To Watch Right Now: Tesla Motors, Inc.(TSLA)

Advisors' Opinion:

• [By Jim Robertson]

  And of course, there is the darling stock and company of the coastal green elites -�electric car stock Tesla Motors Inc��s (NASDAQ: TSLA). Regulators right now have zero interest in looking under the hood�at�Elon Musk��s accounting�or the safety of his products (e.g. autopilot etc) and they certainly aren��t going to start doing so in a Hillary Clinton administration.

• [By Ben Levisohn]

  Shares of Tesla Motors (TSLA) have dropped 5.3% since Donald Trump won the 2016 U.S. presidential election. Some analysts have tried to explain away the move, but Morgan Stanley’s Adam Jonas and team write that they can’t see the election “in a positive light.” They explain why:

  JOHANNES EISELE/AFP/Getty Images

  An environment that moves away from incentivizing electric vehicles is clearly adverse to the story. However, the company was set to exhaust its $7,500 US Federal tax credit for EVs by 2018 anyway and given the very high price point of its vehicles, we don��t believe the incentives were a dominant factor in the purchase decision for these high performance vehicles. Potential removal of incentives for solar adds a headwind to the energy side of the equation, particularly on the eve of the SolarCity (SCTY) acquisition. No direct exposure to Mexico for supply and relatively limited exposure to China for demand may limit the protectionism risk, but a stronger dollar hurts export profit. We cannot see this in a positive light for Tesla.

  Shares of Tesla Motors have declined 0.4% to $184.54 at 11:37 a.m. today, while SolarCity has fallen 0.9% to $19.77.

• [By Spencer Israel]

  Investors wondering about the logic of the proposed Tesla Motors Inc (NASDAQ: TSLA)-SolarCity Corp (NASDAQ: SCTY) merger can rest their hats on this: The deal just does not make sense.

• [By Ben Levisohn]

  Yes, says Axiom Capital’s Gordon Johnson who writes that a Senate investigation into solar company tax incentives could derail Solar City’s (SCTY) merger with Tesla Motors (TSLA). He cites this Wall Street Journal article on the investigation by Brody Mullins, Ianthe Jeanne Dugan, and Richard Rubin, which details why it might be a problem:

• [By David Milstead]

  You can invest in the companies we have long known as the U.S. auto industry. Or you can invest in Tesla Motors (TSLA).

  In reality, of course, you can invest in both. But it��s clear that investors view Tesla as a different breed of automaker. After two quarters of results that delighted investors, Tesla��s shares have risen fivefold this year and, at $160.70, trade at nearly 100 times estimated 2014 earnings (all prices are as of September 9). To invest in Tesla now, you have to buy into the idea that the Palo Alto, Cal., company will move from being a niche player in the luxury-car market to a ��mass market�� seller of revolutionary automobiles that will take a significant chunk of sales away from Ford Motor (F) and General Motors (GM), not to mention foreign automakers.